Progesterone Cream (OTC) — Research Profile

Both contain USP-grade bioidentical progesterone that is structurally identical to the progesterone your body produces. The key differences are dosage control, regulation, and delivery method. Prescription forms (oral Prometrium, vaginal inserts) have more rigorous clinical evidence and predictable blood levels. OTC creams deliver progesterone transdermally with more variable absorption. OTC creams are not FDA-regulated as drugs and thus have less standardized quality control.

Apply to areas with thin skin and good blood flow: inner wrists, inner arms, chest, neck, or inner thighs. Rotate application sites to prevent skin saturation, which can reduce absorption over time. Avoid applying to fatty areas like the abdomen, as progesterone can accumulate in subcutaneous fat rather than entering the bloodstream efficiently.

No. Wild yam contains diosgenin, which is a precursor used in the laboratory synthesis of progesterone, but the human body cannot convert diosgenin into progesterone. Wild yam creams without added USP progesterone will not raise progesterone levels. Always check labels for "USP progesterone" or "progesterone USP" as an ingredient — this indicates actual bioidentical progesterone is included.

Among OTC options, only creams containing micronized progesterone USP hold any active hormone; wild-yam or diosgenin creams do not convert to progesterone in the body and are not a functional substitute. But the transdermal route itself delivers low, erratic blood levels — in a controlled trial even 16–64 mg/day of cream failed to produce the secretory endometrial changes that oral or vaginal progesterone achieves ^[2]. For any use needing a reliable systemic or uterine effect, prescription oral micronized or vaginal progesterone is far better characterized than any cream.

The one clearly demonstrated benefit is relief of menopausal hot flashes: in a 1-year RCT of 20 mg/day cream, 83% of treated women improved versus 19% on placebo (P<.001) ^[1]. In that same trial the cream showed no protective effect on bone mineral density ^[1], and a separate trial found it did not adequately protect the uterine lining during estrogen therapy ^[2]. So the evidence supports vasomotor symptom relief only — not bone, uterine, or broader 'hormone-balancing' claims.

No standardized dose is established. The trial showing hot-flash benefit used 20 mg/day — a quarter-teaspoon of a cream delivering 20 mg per that amount, applied to the skin ^[1] — and common OTC labels similarly provide roughly 20 mg per application. Endometrial-protection studies escalated to 16, 32, and 64 mg/day and still fell short ^[2], so higher amounts have not been shown to buy reliable benefit.

No study has compared times of day, so a 'best' time is not established. Because progesterone tends to cause drowsiness, many people apply it in the evening — a reasonable practical choice rather than an evidence-based one. In cyclic menopausal regimens the cream has been applied on days 15–28 of the cycle ^[2], but that schedule was tested for its effect on the endometrium, not for optimizing symptom timing.

Reported effects mirror systemic progesterone: drowsiness, breast tenderness or enlargement, headache, mood changes, and irregular spotting, plus possible skin irritation at the application site. These tend to track with how much is absorbed, which varies widely between people and products. One marketed OTC cream also carries a California Proposition 65 warning that progesterone is a chemical 'known to the State of California to cause cancer'.

Progesterone is cleared by the liver enzyme CYP3A4, so strong inducers such as rifampin, St. John's wort, and some anti-seizure drugs can lower its blood levels, while inhibitors such as ketoconazole can raise them; it may also add to the sedation of alcohol or other CNS depressants. That said, systemic exposure from OTC creams is low and erratic, so the clinical magnitude of these interactions is uncertain ^[2]. The more consequential issue is pairing the cream with estrogen therapy, because it does not reliably protect the endometrium the way a prescription progestogen does ^[2].

The only group with supporting evidence is women within a few years of menopause seeking hot-flash relief, where a 20 mg/day cream outperformed placebo ^[1]. It should not be relied on by anyone taking estrogen who needs endometrial protection, nor for bone loss, contraception, or fertility support, because it is unproven for those uses ^[1][2]. People with hormone-sensitive conditions should be cautious given the progesterone cancer warning, and no one should treat it as an FDA-vetted therapy.

There is no well-characterized onset. The main placebo-controlled trial applied 20 mg/day (a quarter-teaspoon) of USP progesterone cream and assessed hot-flash relief only after up to 12 months, when 83% of treated women reported improvement versus 19% on placebo — it did not track how quickly symptoms responded ^[1]. Because absorption through skin is low and highly variable between individuals, any timeline is unpredictable, and that same trial showed no benefit for bone density over the year ^[1]; a separate trial found the cream did not adequately protect the endometrium either ^[2].

Long-term safety is not established: the longest controlled trial ran only 12 months ^[1], and these OTC creams are marketed as unapproved drugs that, per their own FDA-mandated labeling, 'FDA has not found... to be safe and effective,' with some carrying a California Proposition 65 progesterone cancer warning. The specific hazard over time is that the cream does not reliably oppose estrogen at the uterine lining, so relying on it for endometrial protection while taking estrogen can permit the overgrowth it is meant to prevent ^[2].

No upper limit has been established, and controlled trials used only about 20 mg/day up to 64 mg/day ^[1][2]. Applying more than labeled raises systemic exposure and the usual dose-related effects — drowsiness, breast tenderness, headache, mood changes, and irregular spotting — rather than causing acute poisoning. Because transdermal absorption is erratic, blood levels from any given amount are unpredictable, so using 'more' does not reliably translate into more effect.

No supplement-combination studies exist for OTC progesterone cream, so any pairing rests on pharmacology rather than data. St. John's wort induces the CYP3A4 enzyme that clears progesterone and can further lower its already-low systemic levels, while sedating botanicals such as valerian or kava could add to progesterone's tendency to cause drowsiness. Note too that creams marketed as 'natural progesterone' from wild yam alone contain no hormone the body can use — there is no evidence the human body converts wild-yam diosgenin into progesterone — so stacking products can unintentionally double or negate a dose.

Check that the label states 'progesterone USP' with a defined amount per measured dose — one marketed cream provides 20 mg per 58 g tube, about 21 mg per pump. Avoid products listing only 'wild yam' or 'diosgenin,' which carry no progesterone the body can use. Remember these are legally unapproved drugs whose labeling 'has not been approved by FDA,' so actual content varies between brands and independent (third-party) assay is worth seeking.